» Articles » PMID: 8515864

Up-regulation of Cholecystokinin in Primary Sensory Neurons is Associated with Morphine Insensitivity in Experimental Neuropathic Pain in the Rat

Overview
Journal Neurosci Lett
Specialty Neurology
Date 1993 Apr 2
PMID 8515864
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the distribution of mRNA for the peptide cholecystokinin (CCK) with in situ hybridization in adult rat lumbar dorsal root ganglia following unilateral section of the sciatic nerve, as well as the effect of systemic CI 988, a selective antagonist of the CCK type B receptor, applied alone or in combination with intrathecal (i.t.) morphine, on the self-mutilating behavior of rats (autotomy) after axotomy, a sign of neuropathic pain and/or dysesthesia. There was a dramatic increase in the number of neurons in dorsal root ganglia synthesizing the peptide cholecystokinin (CCK) after sciatic nerve section. Furthermore, the autotomy behavior of rats was significantly inhibited by chronic i.t. administration of morphine in conjunction with subcutaneous (s.c.) injection of CI 988. Neither i.t. morphine nor s.c. CI 988 alone produced a comparable effect on autotomy. Our results suggested that up-regulation of the mRNA for CCK in primary afferents after nerve injury may be related to the clinical phenomenon of opioid insensitivity. Thus, coadministration of CCK antagonists in combination with opioids may offer a new approach in treating neuropathic pain.

Citing Articles

Unlocking New Therapeutic Options for Vincristine-Induced Neuropathic Pain: The Impact of Preclinical Research.

Puscasu C, Negres S, Zbarcea C, Chirita C Life (Basel). 2024; 14(11).

PMID: 39598298 PMC: 11595627. DOI: 10.3390/life14111500.


Role of HDAC5 Epigenetics in Chronic Craniofacial Neuropathic Pain.

Hui S, Westlund K Int J Mol Sci. 2024; 25(13).

PMID: 38999998 PMC: 11241576. DOI: 10.3390/ijms25136889.


Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.

Bernard A, Mroue M, Bourthoumieu S, Boyce M, Richard L, Sturtz F Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399359 PMC: 10892341. DOI: 10.3390/ph17020144.


Rapid Generation and Molecular Docking Analysis of Single-Chain Fragment Variable (scFv) Antibody Selected by Ribosome Display Targeting Cholecystokinin B Receptor (CCK-BR) for Reduction of Chronic Neuropathic Pain.

Kunamneni A, Montera M, Durvasula R, Alles S, Goyal S, Westlund K Int J Mol Sci. 2023; 24(13).

PMID: 37446213 PMC: 10341521. DOI: 10.3390/ijms241311035.


Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction.

Westlund K, Montera M, Goins A, Alles S, Afaghpour-Becklund M, Bartel R Neurobiol Pain. 2021; 10:100067.

PMID: 34458647 PMC: 8378781. DOI: 10.1016/j.ynpai.2021.100067.